Journal article · 2003
US FDA approves new class of HIV therapeutics
Nature Biotechnology, 21(5), 470–471 · Published 29 April 2003 · DOI 10.1038/nbt0503-470
In brief
“US FDA approves new class of HIV therapeutics” is a 2003 journal article by Debra Robertson, published in Nature Biotechnology. OpenAlex counts 59 citations as of 21 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 59
- Most cited in
- 2014 (4)
- Authors
- 1
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Robertson, D. (2003). US FDA approves new class of HIV therapeutics. Nature Biotechnology, 21(5), 470–471. https://doi.org/10.1038/nbt0503-470
MLA 9
Robertson, Debra. “US FDA approves new class of HIV therapeutics.” Nature Biotechnology, vol. 21, no. 5, 2003, pp. 470–471. https://doi.org/10.1038/nbt0503-470.
Chicago
Robertson, Debra. 2003. “US FDA approves new class of HIV therapeutics.” Nature Biotechnology 21 (5): 470–471. https://doi.org/10.1038/nbt0503-470.
Harvard
Robertson, D. (2003) ‘US FDA approves new class of HIV therapeutics’, Nature Biotechnology, 21(5), pp. 470–471. doi:10.1038/nbt0503-470.
IEEE
D. Robertson, “US FDA approves new class of HIV therapeutics,” Nature Biotechnology, vol. 21, no. 5, pp. 470–471, 2003, doi: 10.1038/nbt0503-470.
BibTeX
@article{robertson2003approves,
title = {{US FDA approves new class of HIV therapeutics}},
author = {Robertson, Debra},
journal = {Nature Biotechnology},
year = {2003},
volume = {21},
number = {5},
pages = {470--471},
doi = {10.1038/nbt0503-470},
url = {https://doi.org/10.1038/nbt0503-470}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2013 | 2 | |
| 2014 | 4 | |
| 2015 | 3 | |
| 2016 | 3 | |
| 2017 | 2 | |
| 2018 | 1 | |
| 2020 | 1 | |
| 2021 | 3 | |
| 2022 | 1 | |
| 2023 | 1 |
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- HIV treatment
- FDA approval
- antiretroviral drugs
- drug approval
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Robertson, D. (2003). US FDA approves new class of HIV therapeutics. Nature Biotechnology, 21(5), 470–471. https://doi.org/10.1038/nbt0503-470
How many times has this paper been cited?
59 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Debra Robertson.
What is the DOI of this paper?
10.1038/nbt0503-470, permanently at https://doi.org/10.1038/nbt0503-470. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.